Thelansis

Acute Myeloid Leukemia (AML) Epidemiology Insights and Disease Burden Thelansis’s “Acute Myeloid Leukemia (AML) Epidemiology Insights and Disease Burden Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . ⁠ Acute Myeloid Leukemia (AML) Overview Acute myeloid leukemia (AML) is an aggressive clonal hematopoietic malignancy arising from myeloid progenitor cells, characterized by the rapid accumulation of immature blast cells in the bone marrow. Somatic mutations in FLT3, NPM1, IDH1, IDH2, and TP53 alongside ...

Acute Myeloid Leukemia (AML) Epidemiology Insights Thelansis’s “Acute Myeloid Leukemia (AML) Global Epidemiology Insights and Disease Burden Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America) . ⁠ Acute Myeloid Leukemia (AML) Overview Acute Myeloid Leukemia (AML) is an aggressive clonal hematopoietic malignancy arising from myeloid progenitor cells, characterized by the rapid accumulat...

Acute Myeloid Leukemia (AML) Epidemiology Insights Thelansis’s “ ⁠ Acute Myeloid Leukemia (AML) Epidemiology Insights and Forecast Report – 2020 To 2040 ″  provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies. Key business questions answered: 20-year historical and forecast data (2020–2040) Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes) Granular patient population coverage by year and geography Detailed segmentation by age, gender, subpopulations, comorbidities, ...